About this trial
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients older than 18 years old
Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study
Disqualifiers
Incomplete clinical data
previous coronary stent implantation
no abdominal ultrasound examination
poor ultrasound image quality
Trial population
All research subjects were from the Second Affiliated Hospital of Chongqing Medical University
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
Observational study without human intervention
Other interventionObservational study without human intervention
Treatment groups
Trial outcomes
Primary outcomes
SYNTAX score
The complexity of coronary artery disease (CAD) is a predictor of cardiovascular events in patients with \>50 % diameter stenosis as determined by SYNTAX score. The range of US-FLI is 0-8. Fatty liver was diagnosed when US-FLI ≥ 2.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.